May 14 2015
Stereotaxis, Inc., a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 36th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 14-16, 2015 in Boston, MA. During the three-day event, the Company will share new clinical evidence, technology enhancements, expert validation and interactive demonstrations of its remote magnetic navigation platform at Booth# 203.
"Our clinical sites continue to generate an abundance of data on the specific advantages of our Niobe® system compared to conventional approaches to cardiac ablation, due to the precise control, high definition mapping and enhanced linear, contiguous lesions that can be achieved during therapy," said William C. Mills, Stereotaxis Chief Executive Officer. "We are particularly pleased to share new evidence around the clinical effectiveness of our magnetic navigation suite in the treatment of ventricular tachycardia (VT), as well as to convene a group of Stereotaxis users who will serve as lead investigators for a prospective, multi-center study to further substantiate the performance benefits of our technologies in the setting of VT."
In the HRS Rhythm Theatre on Friday, May 15, which will be moderated by Dr. Eric N. Prystowsky (St. Vincent's Hospital), Dr. J. David Burkhardt (St. David's Medical Center) will present clinical data on the advantages of magnetic navigation in treating VT, specifically in the areas of contact force and lesion effectiveness, and will share his perspective that the Niobe system may become the standard of care for treatment of VT. Additionally, Dr. Hiroshi Nakagawa (Oklahoma Health Sciences Center) will discuss current scientific research on a novel approach to conducting lesion assessment without requiring contact force measurements. This research also will be presented in abstract form, "Bipolar Impedance Identifies Electrode-Tissue Contact for Radiofrequency Lesion Formation Using the Magnetic Catheter Maneuvering System in the Beating Canine Heart."
HRS will publish several Stereotaxis related scientific abstracts, including a follow-up to a recent publication by Princess Grace Hospital in Monaco, which reported 86.6% freedom from atrial fibrillation (AF) 12 months after ablation therapy with the Niobe system in conjunction with the Vdrive® robotic navigation system. Monaco's Dr. Gabriel Latcu will share additional results on magnetic catheter stability and optimal contact, supported by his 2015 abstract, "Magnetic and Contact-Force Sensing Catheters Have Similar Orientation During Circumferential Pulmonary Vein Isolation: Lessons From Bipolar Electrogram Morphology Analysis." In addition, use of Stereotaxis' Niobe system for VT procedures will be featured in an abstract titled, "Manual Navigation versus Remote Magnetic System for Ventricular Tachycardia Ablation: A Systematic Review of Literature," by Sampath Gunda, et al., underscoring strong performance in all five clinical endpoints.
Other scientific data to be presented include:
- "Feasibility and Safety of a Novel 3-Dimensional RF Energy Monitoring System: Optimizing RF Lesion Formation to Improve AF Ablation Outcomes;" Mauricio S. Arruda, et al.
- "Vdrive™ Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study – The VERSATILE Study in Atrial Fibrillation Ablation;" Georg Noelker, et al.
Furthermore, Dr. Eric Wissner (Asklepios Klinik St. Georg) will share impressive AF outcomes and efficiency data, and Dr. Tamas Szili-Torok (Erasmus Medical Center) will unveil new evidence of increased lesion volume created by the magnetic catheter in a side-by-side comparison to a manual ablation catheter.
On the innovation front, Stereotaxis will showcase the latest version of its Navigant™ user interface, which includes enhancements to the Ablation History module that are designed to improve accuracy by compensating for movement during the respiratory cycle. In addition, for the first time, Stereotaxis will showcase the Vdrive Duo™ System featuring the V-Sono™ ICE catheter manipulator, V-CAS™ catheter advancement system and Vmotion™ automation features that improve operator efficiency by providing automatic orientation of the ICE catheter, offering a continuous view of the ablation catheter.